Clinical trials: Paclitaxel, completed
Endometrial Carcinoma
Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma
Endometrial cancer, the most common gynecologic cancer worldwide, is steadily increasing in developed countries.The early-stage forms of endometrial cancer are usually highly curable by surgical treatment alone, whereas advanced…
- Trial name
- NCT06102252
- Testing
- Paclitaxel/epirubcin/carboplatin, Paclitaxel/carboplatin
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sohag University
Prostate Cancer
Estramustine and Paclitaxel in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005048
- Testing
- estramustine phosphate sodium, paclitaxel
- Where
- 2 sites in United States
- Sponsor
- NYU Langone Health
Advanced Pancreatic Adenocarcinoma
A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer
The Phase Ib/II study is an open-label, single-arm, multicenter trial designed to assess the efficacy and safety of Y101D in combination with Gemcitabine and Albumin Paclitaxel as first-line systemic treatment for advanced…
- Trial name
- NCT06266143
- Testing
- Y101D
- Where
- China
- Volunteers
- 71 people
- Sponsor
- Wuhan YZY Biopharma Co., Ltd.
Breast Cancer
Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer
Primary Objectives: 1. To prospectively evaluate the predictive accuracy of a previously discovered gene expression profile-based test to foretell pathologic complete response (pCR) to preoperative paclitaxel/FAC (5-fluorouracil…
- Trial name
- NCT00336791
- Testing
- 5-Fluorouracil, Cyclophosphamide, Doxorubicin
- Where
- 4 sites in United States, Mexico and 2 more
- Volunteers
- 273 people
- Sponsor
- M.D. Anderson Cancer Center
Chemotherapy-induced Peripheral Neuropathy
A Novel Limb Cryocompression System for Prevention of Chemotherapy Induced Peripheral Neuropathy
The study aims to investigate the safety and tolerability of limb cryocompression in preventing of Chemotherapy-induced Peripheral Neuropathy via a newly developed limb cryocompression device in healthy subjects and cancer…
- Trial name
- NCT05095051
- Testing
- Paxman Cryocompression System (PCCS)
- Where
- Singapore
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Coronary Artery Disease
Optimal Stenting Strategy For True Bifurcation Lesions
It is unclear which stenting strategy will be optimal for true bifurcation coronary lesions.
- Trial name
- PERFECT (NCT00693251)
- Testing
- Crush technique, provisional T stenting
- Where
- 12 sites in South Korea
- Volunteers
- 420 people
- Sponsor
- Seung-Jung Park
Breast Cancer
Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer
Phase III trial to evaluate the efficacy and safety of Genexol®-PM compared to Genexol® in subjects with recurrent or metastatic breast cancer.
- Trial name
- NCT00876486
- Testing
- Genexol-PM®, Genexol®
- Where
- South Korea
- Volunteers
- 213 people
- Sponsor
- Samyang Biopharmaceuticals Corporation
Breast Cancer, Lung Cancer
Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
RATIONALE: Amifostine may be effective in reducing pain, numbness, tingling, and other symptoms of peripheral neuropathy. PURPOSE: This phase II trial is studying how well amifostine works in reducing pain, numbness, tingling…
- Conditions
- Breast Cancer, Lung Cancer, Neurotoxicity, Ovarian Cancer
- Trial name
- NCT00078845
- Testing
- Amifostine
- Where
- 15 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Gastric Cancer
Paclitaxel and Irinotecan in Advanced Gastric Cancer
Usually the combination of fluoropyrimidine with platinum is used as a first line chemotherapy (for example, 5-FU+cisplatin, capecitabine+cisplatin, S-1+ cisplatin, 5-FU+oxaliplatin) in advanced gastric cancer.
- Trial name
- TI-2ndAGC (NCT01136031)
- Testing
- Paclitaxel and irinotecan
- Where
- South Korea
- Volunteers
- 42 people
- Sponsor
- Seoul National University Hospital
Chemotherapeutic Agent Toxicity, Neurotoxicity
Acute Pain Caused by Paclitaxel in Patients With Cancer
RATIONALE: Gathering information over time from patients receiving paclitaxel for cancer may help doctors learn more about pain caused by paclitaxel and plan the best treatment.
- Conditions
- Chemotherapeutic Agent Toxicity, Neurotoxicity, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00860041
- Testing
- pain questionnaires
- Where
- 279 sites in United States
- Volunteers
- 306 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Chemotherapy-induced Peripheral Neuropathy (CIPN)
PREventing CHemotherapy Induced Neuropathy (PreChIN)
The project is designed to study the use of localized hypothermia alone, or with compression to the limbs during chemotherapy infusion for the prevention of chemotherapy induced peripheral neuropathy (CIPN).
- Trial name
- NCT03299582
- Testing
- Hypothermia, Cryocompression
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- National University Hospital, Singapore
Metastatic Breast Cancer, Recurrent Breast Cancer
Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer
This research study is a way of gaining new knowledge about the combination of Taselisib with other drugs in the treatment of metastatic breast cancer.
- Trial name
- NCT02390427
- Testing
- Taselisib, Trastuzumab emtansine, Pertuzumab
- Where
- 3 sites in United States
- Volunteers
- 68 people
- Sponsor
- Nancy Lin, MD
Breast Cancer
Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer
This study will evaluate the efficacy of weekly paclitaxel-carboplatin combination plus bevacizumab as first line treatment in patients with metastatic triple negative breast cancer.
- Trial name
- NCT00691379
- Testing
- Carboplatin, Bevacizumab, Paclitaxel
- Where
- 11 sites in Greece
- Volunteers
- 46 people
- Sponsor
- Hellenic Oncology Research Group
Stable Angina, Unstable Angina
A Trial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary Revascularization in Daily Practice: The COMPARE Trial
Instead of treating in-stent restenosis, the best strategy for patients is preventing in-stent restenosis. Recent advances in the understanding of the cellular mechanism responsible for smooth muscle cell proliferation…
- Conditions
- Stable Angina, Unstable Angina, Acute Coronary Syndrome
- Trial name
- COMPARE 1 (NCT01016041)
- Testing
- everolimus stent, paclitaxel stent
- Where
- Netherlands
- Volunteers
- 1,800 people
- Sponsor
- Maasstad Hospital
Peripheral Artery Disease
ILLUMENATE Pivotal Post-Approval Study (PAS)
The ILLUMENATE Pivotal PAS is a continued follow-up study which will include 300 subjects from forty-three (43) sites across the United States and Austria previously enrolled in the ILLUMENATE Pivotal pre-market study to evaluate…
- Trial name
- NCT03421561
- Testing
- Stellarex 0.035" OTW Drug-coated Angioplasty Balloon, EverCross™ 0.035 PTA Balloon Catheter
- Where
- 41 sites in United States, Austria
- Volunteers
- 300 people
- Sponsor
- Spectranetics Corporation
Ewing's Family Tumors, Renal Tumors
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
This is a standard of care treatment guideline for high risk or relapsed solid tumors or CNS tumors consisting of a busulfan, melphalan, thiotepa conditioning (for solid tumors) or carboplatin and thiotepa conditioning (for CNS…
- Conditions
- Ewing's Family Tumors, Renal Tumors, Hepatoblastoma, Rhabdomyosarcoma
- Trial name
- NCT01505569
- Testing
- Ifosfamide, Etoposide, Mesna
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study is to evaluate the efficacy and safety of tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic esophageal squamous cell carcinoma…
- Trial name
- NCT03783442
- Testing
- Cisplatin, Oxaliplatin, Fluorouracil (5-FU)
- Where
- 124 sites in United States, Australia and 14 more
- Volunteers
- 649 people
- Sponsor
- BeiGene
Coronary Instent Restenosis
A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent
The purpose of this study is to evaluate the efficacy and safety of successful interventional therapy and unblocked blood vessel maintaining in the treatment of coronary in-stent restenosis by paclitaxel -eluting PTCA- balloon…
- Trial name
- PEPCAD (NCT01622075)
- Testing
- SeQuent® Please, Taxus Liberte
- Where
- China
- Volunteers
- 220 people
- Sponsor
- B. Braun Medical International Trading Company Ltd.
Breast Cancer
Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer
This is a prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive breast cancer
- Trial name
- Opti-HER (NCT01669239)
- Testing
- Liposomal Doxorubicin
- Where
- 19 sites in Spain
- Volunteers
- 83 people
- Sponsor
- SOLTI Breast Cancer Research Group
Non-small Cell Lung Cancer
An Open-label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With Non-Small Cell Lung Cancer (NSCLC)
The safety, tolerability, efficacy and pharmacokinetics of ASA404 when administered in combination with paclitaxel and Carboplatin are assessed.
- Trial name
- NCT00674102
- Testing
- ASA404
- Where
- 4 sites in Japan
- Volunteers
- 15 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.